Key facts
- Notable investors include The Engine, Massachusetts Institute of Technology, Bass Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Sutol Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Sutol Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sutol Bio
Developer of a long-acting oral drug delivery designed to provide continuous release of therapeutics over extended periods for patients with chronic conditions. The company uses a monthly capsule dosage form engineered to remain in the gastrointestinal tract for a prolonged duration, enabling controlled multi-week drug release profiles, reducing reliance on daily oral dosing, offering an alternative to long-acting injectables, and supporting medication adherence in outpatient and pharmacy-based treatment settings in worldwide care environments.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2025
- Website
- sutolbio.com/
- Ownership
- Privately Held (backing)
Sutol Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sutol Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sutol Bio in its N-PORT filings yet. We sweep new filings monthly.